D K Solberg1,2, H Bentsen2, H Refsum2, O A Andreassen3,4. 1. Institute for Military Psychiatry, Norwegian Defense Medical Services, Oslo, Norway. 2. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. 3. NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 4. Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Abstract
OBJECTIVE: Earlier reports indicate that patients with schizophrenia have altered lipid levels in serum and cell membranes. The purpose of this study was to determine the relationship between clinical characteristics and serum and membrane lipids. METHOD: Fifty-five patients with schizophrenia and 51 healthy controls were included. The patients were characterized with Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF). Serum lipids [high- and low-density lipoprotein cholesterol (HDL, LDL) and triglyceride (TG)] and erythrocyte polyunsaturated fatty acids (PUFA) were measured. RESULTS: Among the participants with schizophrenia, there was a significant correlation between serum triglyceride levels and PANSS-positive symptoms (r = 0.28, P = 0.04), GAF-S (r = -0.48, P = 0.001) and GAF-F (r = -0.32, P = 0.01), and between HDL level and GAF-S (r = 0.37, P = 0.008) and GAF-F (r = 0.28, P = 0.04). Long-chain PUFA were significantly associated with PANSS-negative symptoms (r = 0.52, P < 0.001), GAF-S (r = -0.32, P = 0.02), and GAF-F (r = -0.29, P = 0.04). The patients with schizophrenia had significantly higher TG (P < 0.001) and lower HDL (P < 0.001) levels than healthy controls. HDL was also lower in the subgroup (n = 11) not receiving antipsychotic medication (P = 0.02). CONCLUSION: The results suggest associations between lipid profile and clinical characteristics. This may indicate a role for lipid biology in schizophrenia pathophysiology.
OBJECTIVE: Earlier reports indicate that patients with schizophrenia have altered lipid levels in serum and cell membranes. The purpose of this study was to determine the relationship between clinical characteristics and serum and membrane lipids. METHOD: Fifty-five patients with schizophrenia and 51 healthy controls were included. The patients were characterized with Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF). Serum lipids [high- and low-density lipoprotein cholesterol (HDL, LDL) and triglyceride (TG)] and erythrocyte polyunsaturated fatty acids (PUFA) were measured. RESULTS: Among the participants with schizophrenia, there was a significant correlation between serum triglyceride levels and PANSS-positive symptoms (r = 0.28, P = 0.04), GAF-S (r = -0.48, P = 0.001) and GAF-F (r = -0.32, P = 0.01), and between HDL level and GAF-S (r = 0.37, P = 0.008) and GAF-F (r = 0.28, P = 0.04). Long-chain PUFA were significantly associated with PANSS-negative symptoms (r = 0.52, P < 0.001), GAF-S (r = -0.32, P = 0.02), and GAF-F (r = -0.29, P = 0.04). The patients with schizophrenia had significantly higher TG (P < 0.001) and lower HDL (P < 0.001) levels than healthy controls. HDL was also lower in the subgroup (n = 11) not receiving antipsychotic medication (P = 0.02). CONCLUSION: The results suggest associations between lipid profile and clinical characteristics. This may indicate a role for lipid biology in schizophrenia pathophysiology.
Authors: Nicholas B Larson; Shannon McDonnell; Lisa Cannon Albright; Craig Teerlink; Janet Stanford; Elaine A Ostrander; William B Isaacs; Jianfeng Xu; Kathleen A Cooney; Ethan Lange; Johanna Schleutker; John D Carpten; Isaac Powell; Joan E Bailey-Wilson; Olivier Cussenot; Geraldine Cancel-Tassin; Graham G Giles; Robert J MacInnis; Christiane Maier; Alice S Whittemore; Chih-Lin Hsieh; Fredrik Wiklund; William J Catalona; William Foulkes; Diptasri Mandal; Rosalind Eeles; Zsofia Kote-Jarai; Michael J Ackerman; Timothy M Olson; Christopher J Klein; Stephen N Thibodeau; Daniel J Schaid Journal: Genet Epidemiol Date: 2017-02-16 Impact factor: 2.135
Authors: Michele M Schantz; Carissa D Powers; Rosemary L Schleicher; Joseph M Betz; Stephen A Wise Journal: Clin Chim Acta Date: 2016-09-20 Impact factor: 3.786
Authors: X Yang; L Sun; A Zhao; X Hu; Y Qing; J Jiang; C Yang; T Xu; P Wang; J Liu; J Zhang; L He; W Jia; C Wan Journal: Transl Psychiatry Date: 2017-07-25 Impact factor: 6.222
Authors: C Tessier; K Sweers; A Frajerman; H Bergaoui; F Ferreri; C Delva; N Lapidus; A Lamaziere; J P Roiser; M De Hert; P Nuss Journal: Transl Psychiatry Date: 2016-10-04 Impact factor: 6.222
Authors: Jamie Joseph; Colin Depp; Pei-An B Shih; Kristen S Cadenhead; Geert Schmid-Schönbein Journal: Front Neurosci Date: 2017-03-27 Impact factor: 4.677